Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials

BACKGROUND: The economic impact of adverse events (AEs) for poly (ADP-ribose) polymerase inhibitors (PARPis) in ovarian or breast cancer has not been widely evaluated. OBJECTIVE: Compare PARPi-related AE management costs from a US payer perspective. METHODS: The frequency of treatment-related grade...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Lin, Zhang, Yuanyuan, Maguire, Peter, Muston, Dominic, Monberg, Matthew, Earla, Jagadeswara Rao, Mihai, Adela, Gulati, Poonam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Routledge 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186353/
https://www.ncbi.nlm.nih.gov/pubmed/35693379
http://dx.doi.org/10.1080/20016689.2022.2078474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186353/
https://www.ncbi.nlm.nih.gov/pubmed/35693379
http://dx.doi.org/10.1080/20016689.2022.2078474

Ejemplares similares